Results 201 to 210 of about 1,712,061 (282)

Peri‐operative management of patients having day surgery: a consensus statement from the Association of Anaesthetists, British Association for Day Surgery and the Association of Paediatric Anaesthetists, Great Britain and Ireland

Anaesthesia, EarlyView.
Summary Introduction Day surgery is now recognised widely as being a vital component of modern healthcare delivery with overall day surgery rates in the UK now > 85%. Day surgery offers an enhanced experience for patients with reduced risk of postoperative complications (e.g.
Craig R. Bailey, David Bunting, Lindsay Hudman, Shivan Kanani, Kirstin May, Catalina Stendall, Rachel Tibble, Allan Xu, Matthew D. Wiles   +8 more
wiley   +1 more source

Patient-reported Itch Outcome Measures for Chronic Pruritus in Dystrophic Epidermolysis Bullosa: Exploratory Analysis of a Phase 2 Randomized Controlled Trial. [PDF]

Acta Derm Venereol
Okata-Karigane U, Gorell ES, Pathmarajah P, Li S, Chiou AS.   +4 more
europepmc   +1 more source

Meta‐Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Alimentary Pharmacology &Therapeutics, EarlyView.
Placebo arms show substantial improvement in cholestatic pruritus, with up to 30% response rate. Estimates differed across outcome instruments, highlighting the importance of endpoint selection and realistic placebo assumptions in future trial design.
Igor Boechat Silveira, Leonardo Corrêa Süffert, Gustavo André Pedral Diniz Leite, Milena Ramos Tomé, Sarah Quick Lourenço de Lima, Gabriel André Pedral Diniz Leite, Bernardo de Faria Moraes, Pedro Robson Costa Passos, Guilherme Grossi Lopes Cançado   +8 more
wiley   +1 more source

Association of comorbidities and drug intake with generalized chronic pruritus: A multicenter case-control study in Switzerland and Italy. [PDF]

JAAD Int
Benzaquen M, Cazzaniga S, Rongioletti F, Pezzolo E, Di Marco G, Naldi L, Borradori L.   +6 more
europepmc   +1 more source

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean, Maryam Yazdanfar, Joseph Zepeda, Isha J. Patel, Cynthia Levy, Craig Lammert, Raghav Bordia, Duru Cosar, Katherine Specht, Daniel Pratt, Stuart C. Gordon, Lisa Forman, Fawzy Barry, Michael Li, Usha Gungabissoon, Megan M. McLaughlin, Christopher L. Bowlus   +16 more
wiley   +1 more source

A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”

Dermatology and Therapy
Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo‑Le‑Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian   +11 more
doaj   +1 more source

Construction and Validation of a Novel "Pruritus Impact Scale" (PIS) for Assessment of Chronic Pruritus. [PDF]

Indian Dermatol Online J
Saugat D, Mittal A, Vyas K, Kaushik PB, Gupta L, Maheshwari K.   +5 more
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Treating Chronic Pruritus: Are We at the Threshold of a Breakthrough? [PDF]

Skin (Milwood)
Smith P, Kranyak A, Johnson CE, Haran K, Liao W, Bhutani T, Koo J.   +6 more
europepmc   +1 more source

Minimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

British Journal of Haematology, EarlyView.
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin   +15 more
wiley   +1 more source